
Claims

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

R^1, R^2, R^3 and R^4 are independently selected from:

(i) H;

(ii) C_{1-3} alkyl, optionally substituted by:

hydroxy,

C_{1-2} alkoxy,

NH_2,

phenyl,

C_{5-6} heteroaryl,

C_{1-4} alkyl carbamoyl, or

acylamido;

(iii) C_{1-3} alkoxy, optionally substituted by C_{3-6} cycloalkyl or by one or more fluoro groups;

(iv) C_{3-6} cycloalkyl;

(v) halo;

(vi) COR^C, where R^C is selected from $NR^{N1}R^{N2}$, where R^{N1} and R^{N2} are independently selected from H and methyl;

(vii) cyano, NH_2, or NO_2; and

(viii) phenyl or C_{5-6} heteroaryl, optionally substituted by methyl, hydroxy or methoxy;

Ar is a phenyl, optionally substituted by one or more groups selected from:

(i) C_{1-4} alkyl, optionally substituted by hydroxy, C_{1-2} alkoxy, NH_2, C_{1-4} alkyl carbamoyl, or by one or more fluoro groups;

(ii) C_{3-6} cycloalkyl;

(iii) hydroxy; cyano; $NR^{N3}R^{N4}$, where R^{N3} and R^{N4} are independently selected from H and methyl; or acylamido;

(iv) halo;

(v) C_{1-3} alkoxy, optionally substituted by hydroxy, $C(O)NH_2$, C_{3-6} cycloalkyl, phenyl, C_{5-6} heteroaryl, or by one or more fluoro groups;

(vi) phenoxy, optionally substituted by fluoro;

(vii) phenyl or C_{5-6} heteroaryl; or

(viii) SF_5 or SO_2CH_3;

and wherein at least one of R^1, R^2, R^3 and R^4 is not H.

2. The compound or salt according to claim 1, wherein at least one of R^1, R^2, R^3 and R^4 is C_{1-3} alkyl, optionally substituted by:

hydroxy,

C_{1-2} alkoxy,

NH_2,

phenyl,

C_{5-6} heteroaryl,

C_{1-4} alkyl carbamoyl, or

acylamido.

3. The compound or salt according to any one of claims 1 to 2, wherein at least one of R^1, R^2, R^3 and R^4 is C_{1-3} alkoxy, optionally substituted by C_{3-6} cycloalkyl or one or more fluoro groups.

4. The compound or salt according to any one of claims 1 to 3, wherein at least one of R^1, R^2, R^3 and R^4 is

(a) C_{3-6} cycloalkyl;

(b) COR^C, where R^C is selected from $NR^{N1}R^{N2}$, where R^{N1} and R^{N2} are independently selected from H and methyl;

(c) cyano, NH_2 or NO_2; or

(d) phenyl or C_{5-6} heteroaryl, optionally substituted by methyl, cyano, hydroxy or methoxy.

5. The compound or salt according to claim 1, wherein:

(a) R^4 is methoxy, R^2 is CH_2OCH_3 or $CH_2OCH_2CH_3$, and R^1 and R^3 are H;

(b) R^4 is methoxy, R^2 is phenyl, optionally substituted by methyl or methoxy, and R^1 and R^3 are H;

(c) R^4 is methoxy, R^2 is C_{5-6} heteroaryl, optionally substituted by methyl;

(d) R^4 is methoxy and R^1, R^2 and R^3 are H;

(e) R^4 is chloro, R^2 is C_{1-3} alkyl or bromo, and R^1 and R^3 are H;

(f) R^4 is chloro and R^1, R^2 and R^4 are H; or
(g) R^3 is C_{1-3} alkyl and R^1, R^2 and R^4 are H.

6. The compound or salt according to any one of claims 1 to 5, wherein Ar is substituted by C_{1-4} alkyl, optionally substituted by hydroxy, C_{1-2} alkoxy, NH_2, C_{1-4} alkyl carbamoyl, or one or more fluoro groups.

7. The compound or salt according to any one of claims 1 to 5, wherein Ar is substituted by C_{1-3} alkoxy, optionally substituted by hydroxy, $C(O)NH_2$, C_{3-6} cycloalkyl, phenyl, C_{5-6} heteroaryl, or one of more fluoro groups.

8. The compound or salt according to any one of claims 1 to 5, wherein Ar is substituted by
(a) C_{3-6} cycloalkyl;
(b) hydroxy;
(c) cyano;
(d) $NR^{N3}R^{N4}$, where R^{N3} and R^{N4} are independently selected from H and methyl; or acylamido;
(e) phenoxy, optionally substituted by fluoro;
(f) phenyl or C_{5-6} heteroaryl; or
(g) SF_5 or SO_2CH_3.

9. The compound or salt according to any one of claims 1 to 5, wherein Ar is:
(a) 5-ethyl-2-methoxyphenyl;
(b) 5-CF_3-2-methoxyphenyl; or
(c) 2,6-dimethoxyphenyl.

10. A pharmaceutical composition comprising a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

11. A compound or salt according to any one of claims 1 to 9, for use in a method of therapy.

12. A compound or salt according to any one of claims 1 to 9, for use in the treatment of cancer.

13. A compound or salt for use according to claim 12, wherein the cancer is selected from leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, non-Hodgkin’s leukemia, Hodgkin’s disease, prostate cancer, lung cancer, melanoma, breast cancer, colon and rectal cancer, colon cancer, squamous cell carcinoma and gastric cancer.

14. A compound or salt for use according to claim 12, wherein the compound is administered simultaneously or sequentially with radiotherapy and / or chemotherapy.